Key result
Cardiovascular comorbidities impair preconditioning signaling cascades, requiring combined therapies to restore cardioprotection.
Why the study?
Cardiovascular co-morbidities such as ageing, diabetes, hyperlipidaemia, hypertension, and chronic kidney disease impair preconditioning stimuli and limit their clinical translation.
Cardiovascular comorbidities impair the protective effects of preconditioning in ischaemic heart disease, necessitating targeted strategies to overcome this limitation in clinical translation.
Answers are grounded in this paper and cite their sources.
May support preconditioning despite comorbidities; extends experimental mechanisms to human RCT outcomes.
Preconditioning has emerged as a promising approach in the management of ischaemic heart diseases. Ischaemic and pharmacological preconditioning have shown their ability to reduce myocardial infarct size and preserve cardiac function in various experimental and clinical settings. The underlying protective mechanisms of preconditioning involve the activation of signalling cascades that promote cell survival, inhibit cell damage and improve cellular energetics. However, the presence of cardiovascular co-morbidities such as ageing, diabetes, hyperlipidaemia, hypertension and chronic kidney disease is known to impair preconditioning stimuli and limit their effectiveness upon translation to clinical practice. This review discusses the impact of these co-morbidities on preconditioning signalling cascades and strategies to overcome this impairment by targeting comorbidity-specific pathways; using various preconditioning triggers, employing combined therapies and amplifying preconditioning stimuli. Additionally, bridging the gap between experimental and clinical studies through well-designed clinical trials is crucial for guaranteeing the feasibility and efficacy of preconditioning interventions in cardiovascular patients with diverse comorbidities.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2026) conducted a review in Ischaemic heart diseases with cardiovascular co-morbidities. Preconditioning (ischaemic and pharmacological) was evaluated. Cardiovascular co-morbidities such as ageing, diabetes, and hypertension impair preconditioning signalling cascades, necessitating targeted strategies and combined therapies to restore cardioprotection.
Synapse has enriched 10 related papers. Consider them for comparative context: